Gut Health Research

Rifaximin shows consistent clinical efficacy for IBS-D patients, reducing symptoms with a relatively low 16.7% adverse event rate

For many with irritable bowel syndrome with constipation (IBS-C), symptom management can be a frustrating search for what works

Here is a comprehensive, evidence-based pillar article on gut health and IBS/SIBO, meticulously crafted per your detailed instructions for maximum autho…

IBS-C Constipation Treatment Management: Integrating Natural Products and Meal Timing Constipation-predominant irritable bowel syndrome (IBS-C) challeng…

Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: Overlap, Recurrence, and Evidence-Based Treatment A 2026 systematic review of 55 cli…

Introduction Short-chain fatty acids (SCFAs) like butyrate are not just byproducts of digestion

Evidence-Based IBS-C Constipation Treatment Management Irritable bowel syndrome with constipation (IBS-C) remains a complex challenge, where simple laxa…

A 2026 Systematic Review Clarifies Best Treatments for SIBO-IBS Symptom Overlap In a 2026 systematic review published in World J Methodol , researchers …

Pathophysiology-Driven Natural Products for IBS-C A 2026 review in Naunyn-Schmiedeberg’s Archives of Pharmacology consolidates evidence that certain nat…

A systematic review published in 2026 analyzed 55 clinical trials and found the antibiotic rifaximin to be the most consistently effective treatment for…

Evidence-Based IBS-C Constipation Treatment: A 2026 Research Update Irritable Bowel Syndrome with constipation (IBS-C) is characterized by chronic abdom…

Rifaximin Efficacy of 83.3% Drives Treatment for IBS and SIBO Overlap A 2026 systematic review of 55 studies analyzed the comparative effectiveness of M…